Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus.
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2015
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 07 Jul 2015 New trial record